Information and interesting ideas

Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.

Friday, May 12, 2023

FDA Webinar: Overview: Clinical Pharmacology Considerations for Food Effect Studies

For those who participate in or support food effect studies a good opportunity to hear FDA perspectives on the guidance

Date:  June 15, 2023

Time:1:00 PM - 2:00 PM ET
Registration link 

In this webinar, FDA will discuss:

  • Importance of assessing the effect of food on drugs and reasons for issuing the final guidance
  • Timing of conducting food effect studies during drug development
  • General considerations for designing food effect studies
  • Other considerations related to assessing the effect of food on a drug

TOPICS COVERED

  • Timing of conducting food effect studies during drug development
  • Type of meals to be evaluated
  • General considerations for designing food effect studies

LEARNING OBJECTIVES

  • Understand the importance of assessing the effect of food on drugs
  • Comprehend general considerations for designing food effect studies
  • Discuss data analysis considerations related to food effect assessment

FDA SPEAKERS

Vikram Arya, Ph.D., FCP
Associate Director for Therapeutic Review, Division of Infectious Disease Pharmacology | Office of Clinical Pharmacology| CDER | FDA

Panelists

Vikram Arya, Ph.D., FCP
Associate Director for Therapeutic Review, Division of Infectious Disease Pharmacology | Office of Clinical Pharmacology| CDER | FDA

Brian Booth, Ph.D.
Director; Division of Cancer Pharmacology I | Office of Clinical Pharmacology | CDER | FDA

Ethan Stier, Ph.D.
Associate Director for Lifecycle Management, Immediate Office | Office of Clinical Pharmacology | CDER | FDA

 

No comments:

Post a Comment

FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made

This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...